AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,282,396 | +66.2% | 92,218 | +90.1% | 0.00% | +50.0% |
| Q2 2023 | $1,373,492 | +23.3% | 48,499 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $1,114,022 | -39.2% | 48,499 | -25.6% | 0.00% | -50.0% |
| Q4 2022 | $1,830,788 | +14.9% | 65,199 | +16.8% | 0.00% | 0.0% |
| Q3 2022 | $1,594,000 | +11.2% | 55,799 | -13.8% | 0.00% | 0.0% |
| Q2 2022 | $1,434,000 | -30.3% | 64,699 | -8.4% | 0.00% | 0.0% |
| Q1 2022 | $2,057,000 | -27.9% | 70,655 | -18.6% | 0.00% | 0.0% |
| Q4 2021 | $2,854,000 | -9.1% | 86,815 | +27.7% | 0.00% | -33.3% |
| Q3 2021 | $3,138,000 | +1.7% | 67,995 | +5.9% | 0.00% | 0.0% |
| Q2 2021 | $3,087,000 | -9.6% | 64,195 | -2.9% | 0.00% | -25.0% |
| Q1 2021 | $3,413,000 | +35.4% | 66,084 | +13.6% | 0.00% | +33.3% |
| Q4 2020 | $2,520,000 | +15.6% | 58,168 | -6.6% | 0.00% | 0.0% |
| Q3 2020 | $2,179,000 | -34.6% | 62,268 | 0.0% | 0.00% | -40.0% |
| Q2 2020 | $3,330,000 | +106.4% | 62,268 | +36.9% | 0.01% | +66.7% |
| Q1 2020 | $1,613,000 | -23.3% | 45,468 | +3.2% | 0.00% | 0.0% |
| Q4 2019 | $2,104,000 | +41.6% | 44,068 | -3.9% | 0.00% | +50.0% |
| Q3 2019 | $1,486,000 | -37.2% | 45,868 | -3.4% | 0.00% | -50.0% |
| Q2 2019 | $2,368,000 | -33.3% | 47,468 | -9.9% | 0.00% | -20.0% |
| Q1 2019 | $3,552,000 | +85.2% | 52,668 | +26.6% | 0.01% | +66.7% |
| Q4 2018 | $1,918,000 | -54.4% | 41,600 | -23.7% | 0.00% | -50.0% |
| Q3 2018 | $4,203,000 | -10.1% | 54,500 | -1.8% | 0.01% | -14.3% |
| Q2 2018 | $4,675,000 | -2.1% | 55,500 | -5.0% | 0.01% | 0.0% |
| Q1 2018 | $4,776,000 | +139.8% | 58,400 | +67.6% | 0.01% | +133.3% |
| Q4 2017 | $1,992,000 | -11.7% | 34,843 | +3.1% | 0.00% | 0.0% |
| Q3 2017 | $2,256,000 | +46.1% | 33,800 | +12.7% | 0.00% | +50.0% |
| Q2 2017 | $1,544,000 | -7.5% | 30,000 | +4.9% | 0.00% | -33.3% |
| Q1 2017 | $1,670,000 | +58.1% | 28,600 | +13.0% | 0.00% | +50.0% |
| Q4 2016 | $1,056,000 | -2.9% | 25,300 | +22.8% | 0.00% | 0.0% |
| Q3 2016 | $1,088,000 | +96.7% | 20,600 | +56.1% | 0.00% | +100.0% |
| Q2 2016 | $553,000 | +169.8% | 13,200 | +355.2% | 0.00% | – |
| Q3 2015 | $205,000 | -36.3% | 2,900 | 0.0% | 0.00% | -100.0% |
| Q2 2015 | $322,000 | +17.9% | 2,900 | 0.0% | 0.00% | – |
| Q1 2015 | $273,000 | -9.9% | 2,900 | +7.4% | 0.00% | -100.0% |
| Q4 2014 | $303,000 | – | 2,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |